Leukotriene C 4 (LTC 4 ) and its extracellular metabolites, LTD 4 and LTE 4 , mediate airway inflammation. They signal through three specific receptors (type 1 cys-LT receptor [CysLT 1 R], CysLT 2 R, and GPR99) with overlapping ligand preferences. In this article, we demonstrate that LTC 4 , but not LTD 4 or LTE 4 , activates mouse platelets exclusively through CysLT 2 R. Platelets expressed CysLT 1 R and CysLT 2 R proteins. LTC 4 induced surface expression of CD62P by wildtype mouse platelets in platelet-rich plasma (PRP) and caused their secretion of thromboxane A 2 and CXCL4. LTC 4 was fully active on PRP from mice lacking either CysLT 1 R or GPR99, but completely inactive on PRP from CysLT 2 R-null (Cysltr2 2/2 ) mice. LTC 4 /CysLT 2 R signaling required an autocrine ADP-mediated response through P2Y 12 receptors. LTC 4 potentiated airway inflammation in a platelet-and CysLT 2 R-dependent manner. Thus, CysLT 2 R on platelets recognizes LTC 4 with unexpected selectivity. Nascent LTC 4 may activate platelets at a synapse with granulocytes before it is converted to LTD 4 , promoting mediator generation and the formation of leukocyte-platelet complexes that facilitate inflammation. The Journal of Immunology, 2013, 191: 5807-5810. C ysteinyl leukotrienes (cys-LTs) play a validated role in asthma (1). After 5-lipoxygenase oxidizes arachidonic acid to LTA 4 (2), eosinophils, basophils, mast cells, and monocytes conjugate LTA 4 to reduced glutathione via leukotriene (LT) C 4 synthase (LTC 4 S) (3), forming LTC 4 . After export, LTC 4 is converted to LTD 4 (4), a smooth muscle spasmogen, and then to LTE 4 (5), a stable metabolite. Three G protein-coupled receptors, termed the type 1 cys-LT receptor (CysLT 1 R) (6, 7), type 2 cys-LT receptor (CysLT 2 R) (8, 9) , and GPR99 (10), mediate the effects of cys-LTs. CysLT 1 R is a high-affinity LTD 4 receptor with lower affinity for LTC 4 (6, 7) . CysLT 2 R binds LTC 4 and LTD 4 with equal affinity (8, 9) , and GPR99 exhibits a preference for LTE 4 (10) . CysLT 1 R-selective antagonists are widely prescribed for asthma (11) . Although CysLT 2 R inhibits dendritic cell priming for Th2 immune responses (12) and GPR99 mediates LTE 4 -induced skin edema (10), our understanding of the therapeutic applicability of these receptors is limited. Moreover, because many cell types express more than one cys-LT receptor, assignment of receptor-specific functions through in vitro approaches is challenging.
Platelets play an important role in asthma (13) and vascular inflammation (14) . Platelets adhere to granulocytes by a CD62P (P-selectin)-P-selectin glycoprotein-1-dependent mechanism. Adherent platelets upregulate leukocyte integrin avidity (15) and permit transcellular metabolism of arachidonic acid (16) . Platelets contain LTC 4 S and convert granulocytederived LTA 4 to LTC 4 through a transcellular pathway, amplifying the production of cys-LTs (13) . Human platelets express both CysLT 1 R and CysLT 2 R (17). To date, however, no study has definitively addressed whether cys-LTs influence platelet functions or determined which receptors are most essential.
We report that LTC 4 , but not LTD 4 or LTE 4 , activates mouse platelets entirely through CysLT 2 R. LTC 4 induces expression of platelet CD62P. This response requires CysLT 2 R, but not CysLT 1 R or GPR99. LTC 4 induces platelets to release inflammatory mediators, and to augment allergen-induced airway inflammation. CysLT 2 R-dependent platelet activation requires amplification from P2Y 12 receptors and ADP. LTC 4 may facilitate local activation of platelets in a synapse with leukocytes, in turn amplifying inflammatory responses. This function is distinct from those of its extracellular metabolites. Moreover, CysLT 2 R can function as an LTC 4 receptor with high specificity despite its ability to bind LTD 4 in transfected cells (8) . 
Materials and Methods

Animals Tbxa2r
2/2 mice were obtained from Dr. Thomas Coffman (Duke University, Durham, NC) (18). P2ry12 2/2 mice were from Portola Pharmaceuticals (San Francisco, CA) (19) . Cysltr1 2/2 , Cysltr2 2/2 , and Gpr99 2/2 mice were generated in our institution (10, 20, 21) . Mice were sensitized i.p. on days 0 and 7 with Alum-precipitated chicken egg OVA (10 mg; Sigma) and challenged by inhalation of 0.1% OVA with or without intranasal cys-LTs as described previously (22) . Platelets were depleted by an i.p. injection of an anti-CD41 Ab (clone MWReg30; Biolegend, San Diego, CA) or an isotype control (23) .
Platelet isolation
Blood was obtained by cardiac puncture using a 21G needle into 4% sodium citrate (Sodium Citrate Enzyme Grade; Fisher Scientific, Pittsburgh, PA). Platelet-rich plasma (PRP) was obtained by slow-spin centrifugation of whole blood at 1000 rpm/900 3 g for 15 min. PRP was incubated with CaCl 2 (Fisher) ([final]= 5 mM) at 37˚C for 10 min.
Platelet activation
Aliquots of PRP (50 ml) were stimulated with thrombin (50 U/ml; Sigma Aldrich, St. Louis, MO), LTC 4 , LTD 4 , or LTE 4 (25-250 nM; Cayman Chemical, Ann Arbor, MI) at 37˚C for 30 min. Samples were stained with PE anti-mouse CD41 (clone MWReg30; Biolegend) and FITC rat anti-mouse CD62P (clone RB40.34; BD Pharmingen, San Diego, CA) for analysis of CD62P expression on CD41 + mouse platelets. PE rat IgG1k and FITC rat IgG1l were used for isotype controls (BD Pharmingen). Cells were fixed overnight in 1% paraformaldehyde in PBS (Affymetrix, Cleveland, OH). Some aliquots of PRP were stimulated with at 37˚C for 30 min for analysis of released thromboxane (Thromboxane B 2 EIA Kit; Cayman), RANTES (eBioscience, San Diego, CA) and CXCL4 (Sigma) by ELISA, or for ADP (Abcam). Some samples were treated with the CysLT 2 R antagonists BayCysLT 2 and HAMI3379 (300 nM each; Cayman Chemical). In some experiments, supernatants were analyzed for conversion of LTC 4 to LTD 4 and LTE 4 by high-performance liquid chromatography (3). (25) . Because extracellular enzymes efficiently convert LTC 4 to LTD 4 and LTE 4 , LTC 4 most likely functions in a synapse between the cells of origin and adjacent endothelium or platelets. However, apart from its role as a precursor, no unique functions have been attributed to LTC 4 . Human platelets express both CysLT 1 R and CysLT 2 R (17), as is the case for many hematopoietic cells (24) . Given that cell recruitment (26), bronchoconstriction (27) , airway inflammation (22) , and fibrosis (20) all involve both cys-LTs and platelet activation (13, 22, 28, 29) , we sought to determine whether platelets might respond directly to cys-LTs.
Results and Discussion
We first stimulated platelets from wild-type (WT) mice with various concentrations of LTC 4 , LTD 4 , and LTE 4 . Only LTC 4 elicited an increase in surface CD62P expression ( Fig.  1) and was active at the lowest dose tested (25 nM). The response to LTC 4 at 250 nM was ∼60% of that elicited by FIGURE 1. Platelet activation by cys-LTs. PRP from WT mice was stimulated with the indicated agonists. CD62P was assessed by flow cytometry. Results are mean 6 SD from 5-10 separate experiments using platelets from 1 mouse/strain. thrombin (Fig. 1) . PRP did not convert LTC 4 to LTD 4 or LTE 4 (not shown). The induction of CD62P by LTC 4 , and the lack of any response to LTD 4 and LTE 4 at physiologic ranges, suggests that LTC 4 has specific functions in the formation of platelet-leukocyte complexes, which depend on induction of CD62P and its interaction with (P-selectin)-Pselectin glycoprotein-1 on the leukocyte surface (25) .
Given that CysLT 1 R and CysLT 2 R each bind LTC 4 and LTD 4 at low nanomolar ranges (6, 9) , the response limited to LTC 4 was unexpected. To identify the responsible receptors, we stimulated PRP obtained from mice lacking CysLT 1 R (Cysltr1 2/2 mice), CysLT 2 R (Cysltr2 2/2 mice), and GPR99 (Gpr99 2/2 mice). Platelets from Cysltr2 2/2 mice were unresponsive to LTC 4 ( Fig. 2A) , whereas platelets from the Cysltr1 2/2 ( Fig. 2B) and Gpr99 2/2 strains (Fig. 2C) were fully responsive. Platelets from all three strains responded to thrombin, and none reacted to LTD 4 or LTE 4 ( Fig. 2A-C) . Platelets from WT mice expressed both CysLT 1 R and CysLT 2 R proteins, as did human platelets (Fig. 2D) . Thus, whereas recombinant CysLT 2 R has equal binding affinities for LTC 4 and LTD 4 (8, 9) , natively expressed CysLT 2 R on mouse platelets exhibits a preference for activation by LTC 4 . Moreover, despite the presence of CysLT 1 R on platelets, CysLT 2 R is the dominant effector of responses to LTC 4 in this cell type. In mast cells (30) and dendritic cells (12) , CysLT 1 R signaling dominates and CysLT 2 R serves an inhibitory function. Cellspecific variations in receptor stoichiometry, relative abundances, localization, or G protein coupling may account for these functional differences.
Endogenous ADP can amplify platelet activation through P2Y 1 and P2Y 12 receptors (31). P2Y 12 receptors are implicated in cellular responses to cys-LTs (particularly LTE 4 ) (22, 32), but do not bind cys-LTs (22) , suggesting an indirect functional relationship to cys-LT receptors. LTC 4 -mediated induction of CD62P was markedly impaired in P2ry12 2/2 platelets (Fig. 3A) . Treatment of WT platelets with apyrase attenuated their responses to LTC 4 (Fig. 3B ) while depleting extracellular ADP (Fig. 3C) . Although the doses of LTE 4 used in this study may exceed those required to demonstrate activity at P2Y 12 , only LTC 4 caused platelets to release ADP; this response required CysLT 2 R (Fig. 3C ). P2Y 12 -targeted thienopyridine drugs, which prevent cardiovascular events (33) , may interfere with the LTC 4 /CysLT 2 R-dependent pathway of platelet activation in vivo.
Activated platelets generate thromboxane A 2 (TXA 2 ), a potent inflammatory mediator, and secrete chemokines (34) . Human platelets released RANTES when stimulated with cysLTs in a prior study (17) . In our study, LTC 4 induced mouse platelets to release large quantities of TXA 2 , as well as CXCL4 and, to a lesser extent, RANTES (Supplemental Fig. 1A-C) , in a CysLT 2 R-and P2Y 12 receptor-dependent manner. Two CysLT 2 R antagonists, BayCysLT 2 and HAMI3379 (300 nM each), suppressed TXA 2 release by WT platelets (Supplemental Fig. 1D ). Studies using platelets from Tbxa2r 2/2 mice revealed that TXA 2 was not necessary for LTC 4 -induced activation, although there was a trend toward less activation at the lowest LTC 4 doses (Supplemental Fig. 2 ).
Intrapulmonary administration of LTE 4 to sensitized mice challenged with low-dose OVA potentiates eosinophil recruitment in a platelet-and P2Y 12 -dependent manner (35) . We treated sensitized mice intranasally with LTC 4 (2 nmol) on 3 consecutive days before low-dose (0.1%) OVA challenges. LTC 4 markedly potentiated the recruitment of eosinophils to the bronchoalveolar lavage (BAL) fluid. This response depended on CysLT 2 R, P2Y 12 (Fig. 4A), and platelets (Fig. 4B) . LTC 4 may therefore contribute to platelet activation in asthma, aspirin-exacerbated respiratory disease (13), myocardial infarction (36) , and stroke (37) . Moreover, this pathway likely resists blockade by the available antagonists, which do not target CysLT 2 R, but may be sensitive to P2Y 12 receptor-active drugs.
